Analyzing walking ability in patients with facioscapulohumeral muscular dystrophy
Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular Dystrophies
This study is testing how facioscapulohumeral muscular dystrophy affects walking ability in patients to see if it can help improve their mobility and quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT06600308 on ClinicalTrials.gov |
What this trial studies
This study focuses on individuals diagnosed with facioscapulohumeral muscular dystrophy (FSH), a genetic condition that leads to progressive muscle weakness and walking difficulties. It aims to assess the functional impact of FSH on walking ability through various walk tests and ecological assessments in real-life settings. By understanding these walking challenges, the study seeks to inform potential therapeutic interventions that could improve patients' mobility and quality of life. Participants will undergo a series of tests to evaluate their walking capabilities over a six-minute period.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with a confirmed genetic diagnosis of facioscapulohumeral muscular dystrophy who can walk for at least six minutes.
Not a fit: Patients with significant cardiorespiratory issues or other neuro-orthopaedic conditions that impair walking ability may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved therapeutic strategies that enhance walking ability and overall mobility for patients with FSH.
How similar studies have performed: While there is ongoing research into gene therapies for FSH, this specific focus on walking analysis is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patient : * Adult ; * Having given written consent; * With an established molecular genetic diagnosis of FSH; * Able to understand the instructions for carrying out the various tests; * Able to walk for at least 6 minutes, even intermittently; Exclusion Criteria: Patient : * Not affiliated to or not benefiting from a social security scheme; * With one or more cardiorespiratory contraindications to a 6-minute test; * With another neuro-orthopaedic history (other than FSH) that could significantly compromise walking ability; * With cognitive problems preventing them from performing standardised tasks; * Under legal protection (curatorship, guardianship). * Who are subject to a legal protection measure; * Pregnant, parturient or breast-feeding woman; * Unable to benefit from longitudinal follow-up (D15 and M6).
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Nawale HADOUIRI
- Email: nawale.hadouiri@chu-dijon.fr
- Phone: 0380669073
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.